VanEck Biotech ETF (BBH) |
| 253.2727 3.471 (1.39%) 10-28 16:00 |
| Open: | 247.38 |
| High: | 254.75 |
| Low: | 247.375 |
| Volume: | 19,305 |
| Market Cap: | 516(M) |
| PE Ratio: | 29.87 |
| Exchange: | NASDAQ Global Market |
| Industry: | Asset Management |
| Sector: | Financial Services |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 297.55 |
| Resistance 1: | 254.75 |
| Pivot price: | 244.29 |
| Support 1: | 239.62 |
| Support 2: | 230.26 |
| 52w High: | 254.75 |
| 52w Low: | 176.3 |
The VanEck Biotech ETF (BBH) aims to closely reflect the price appreciation and income yield of the MVIS US Listed Biotech 25 Index (MVBBHTR), prior to the deduction of fees and expenses. This index monitors the aggregate performance of corporations involved in the research, manufacturing, promotion, and sale of medications derived from genetic insights and diagnostic technologies.
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Wed, 28 Oct 2026
ETFs That You May Consider Amid a Strengthening Biotech Outlook - TradingView
Tue, 27 Oct 2026
Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool
Sun, 25 Oct 2026
VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? - The Motley Fool
Thu, 22 Oct 2026
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool
Wed, 21 Oct 2026
Biotech ETF (BBH) Hits New 52-Week High - Yahoo Finance
Sat, 10 Oct 2026
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma - The Motley Fool
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
